Drug Development & Delivery included an in-depth article on Affibody and its unique approach to radiopharma, and the clinical success of lead RLT candidate, ABY-271, which is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer. 

Read the full article here.